Valérie Decostre
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Valérie Decostre has a total of 201 co-authors. Here are the top co-authors by number of shared publications:
- Jean-Yves Hogrel
Neuromuscular Physiology and Evaluation Laboratory, Neuromuscular Investigation Center, Institute of Myology, Paris, France
9 shared publications Pascal Laforêt
APHP, Department of Neurology, Raymond Poincaré Hospital, Centre de Référence de Pathologie Neuromusculaire Nord/Est/Ile-de-France, Garches, France; INSERM U1179, Université Versailles Saint-Quentin-en-Yvelines, Montigny-le-Bretonneux, France
4 shared publications- Anthony Behin
Institut de Myologie, Centre de Référence de Pathologie Neuromusculaire Paris-Est, GH Pitié-Salpêtrière, Paris, France
3 shared publications Aurélie Canal
3 shared publicationsGwenn Ollivier
3 shared publications- Marie De Antonio
CHU Clermont-Ferrand, Biostatistics Unit, Clermont-Ferrand, France
3 shared publications
Latest Publications
- Open Access
- 4 May 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (5) , 301
Prospective gait analysis in patients from the French registry of glycogen storage disease type III: implications for clinical trials
Background and objectives Glycogen storage disease type III (GSD-III) is a genetic metabolic disorder affecting liver and muscle, frequently leading to walking difficulties in adults. This study aimed to quantify walking performance and its progression in GSD-III, identify relevant outcome measures for future clinical trials, and determine predictors of gait decline. Methods Participants enrolled in the French GSD-III registry underwent an annual assessment of their 6-min walk distance (6MWD) combined with 3D trunk accelerometry. Muscle strength for flexion and extension of the knee and ankle, as well as Motor Function Measure (MFM) scores, were also collected. Results Among registry participants, 93% were ambulant without assistance. The 6MWD of participants with GSD-III (n = 46, aged 10–49 years) was lower than that of controls (n = 53) (adjusted p < 0.001), due to reduced stride frequency and stride length/height ratio (adjusted p < 0.001). Accelerometry revealed no abnormalities beyond those related to slower walking speed. 6MWD correlated with muscle strength and accelerometry variables. In adults, total MFM score declined with age (adjusted p < 0.001), whereas 6MWD remained stable overall, despite a gradual decline in a few patients. Preliminary models suggest that lower baseline MFM sub-scores and specific trunk accelerometry variables may predict 6MWD deterioration. Discussion The walking impairment remains stable in most patients. MFM sub-scores and accelerometry variables may help identify the rare individuals at risk of gait decline. Unlike 6MWD, total MFM score worsened in adulthood and appears to be the most relevant muscle outcome measure for future clinical trials in GSD-III. French GSD-III Registry registration number NCT06616545 was retrospectively registered on 27 SEP 2024.
- 4 May 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (5) , 301
Open AccessProspective gait analysis in patients from the French registry of glycogen storage disease type III: implications for clinical trials
Background and objectives Glycogen storage disease type III (GSD-III) is a genetic metabolic disorder affecting liver and muscle, frequently leading to walking difficulties in adults. This study aimed to quantify walking performance and its progression in GSD-III, identify relevant outcome measures for future clinical trials, and determine predictors of gait decline. Methods Participants enrolled in the French GSD-III registry underwent an annual assessment of their 6-min walk distance (6MWD) combined with 3D trunk accelerometry. Muscle strength for flexion and extension of the knee and ankle, as well as Motor Function Measure (MFM) scores, were also collected. Results Among registry participants, 93% were ambulant without assistance. The 6MWD of participants with GSD-III (n = 46, aged 10–49 years) was lower than that of controls (n = 53) (adjusted p < 0.001), due to reduced stride frequency and stride length/height ratio (adjusted p < 0.001). Accelerometry revealed no abnormalities beyond those related to slower walking speed. 6MWD correlated with muscle strength and accelerometry variables. In adults, total MFM score declined with age (adjusted p < 0.001), whereas 6MWD remained stable overall, despite a gradual decline in a few patients. Preliminary models suggest that lower baseline MFM sub-scores and specific trunk accelerometry variables may predict 6MWD deterioration. Discussion The walking impairment remains stable in most patients. MFM sub-scores and accelerometry variables may help identify the rare individuals at risk of gait decline. Unlike 6MWD, total MFM score worsened in adulthood and appears to be the most relevant muscle outcome measure for future clinical trials in GSD-III. French GSD-III Registry registration number NCT06616545 was retrospectively registered on 27 SEP 2024.
- Open Access
- 17 March 2026
- Published by SAGE Publications in Journal of Neuromuscular Diseases
- Vol. 13 (6) , 1200-1214
Sexual health in neuromuscular diseases: Neglected challenges revealed by a scoping review
Background: Neuromuscular diseases (NMDs) are heterogeneous disorders causing progressive motor decline, multisystem complications, and reduced quality of life. Sexual health, a key component of well-being, remains largely overlooked. This scoping review mapped and synthesized evidence on sexual dysfunction (SD) in adults with NMDs, focusing on prevalence, underlying mechanisms, and research gaps. Methods: A systematic search of PubMed, Cochrane Library, and Google Scholar (February–March 2025) identified studies reporting original data on SD in adults with genetically or clinically confirmed NMDs. Citation tracking complemented the search. Data were narratively synthesized following PRISMA-ScR guidelines. Results: Twenty-seven studies (1983–2024) including 2428 individuals met the inclusion criteria. Most were cross-sectional and questionnaire-based studies. SD was frequent but heterogeneous across conditions. In myotonic dystrophy, erectile dysfunction often related to hypogonadism; in Charcot-Marie-Tooth disease, higher disease severity correlated with altered desire and satisfaction in women; amyloid neuropathies showed autonomic-related erectile and ejaculatory dysfunction in men and multidimensional impairment in women; inflammatory myopathies revealed high SD prevalence in both sexes; amyotrophic lateral sclerosis involved intimacy loss mainly due to disability and psychosocial distress, despite preserved interest; myasthenia gravis displayed SD mainly associated with mental health conditions, X-linked spinal muscular atrophy showed predominantly endocrine-related SD. Conclusion: SD is common, multifactorial, and under-recognized in adults with NMDs. The available evidence remains limited by non-inclusive approaches to sexual orientation and intimacy, scarce physiological assessments, and substantial gaps regarding female sexual health, longitudinal data. Integrating sexual health assessment into routine care for people with NMDs should be prioritized.
- 17 March 2026
- Published by SAGE Publications in Journal of Neuromuscular Diseases
- Vol. 13 (6) , 1200-1214
Open AccessSexual health in neuromuscular diseases: Neglected challenges revealed by a scoping review
Background: Neuromuscular diseases (NMDs) are heterogeneous disorders causing progressive motor decline, multisystem complications, and reduced quality of life. Sexual health, a key component of well-being, remains largely overlooked. This scoping review mapped and synthesized evidence on sexual dysfunction (SD) in adults with NMDs, focusing on prevalence, underlying mechanisms, and research gaps. Methods: A systematic search of PubMed, Cochrane Library, and Google Scholar (February–March 2025) identified studies reporting original data on SD in adults with genetically or clinically confirmed NMDs. Citation tracking complemented the search. Data were narratively synthesized following PRISMA-ScR guidelines. Results: Twenty-seven studies (1983–2024) including 2428 individuals met the inclusion criteria. Most were cross-sectional and questionnaire-based studies. SD was frequent but heterogeneous across conditions. In myotonic dystrophy, erectile dysfunction often related to hypogonadism; in Charcot-Marie-Tooth disease, higher disease severity correlated with altered desire and satisfaction in women; amyloid neuropathies showed autonomic-related erectile and ejaculatory dysfunction in men and multidimensional impairment in women; inflammatory myopathies revealed high SD prevalence in both sexes; amyotrophic lateral sclerosis involved intimacy loss mainly due to disability and psychosocial distress, despite preserved interest; myasthenia gravis displayed SD mainly associated with mental health conditions, X-linked spinal muscular atrophy showed predominantly endocrine-related SD. Conclusion: SD is common, multifactorial, and under-recognized in adults with NMDs. The available evidence remains limited by non-inclusive approaches to sexual orientation and intimacy, scarce physiological assessments, and substantial gaps regarding female sexual health, longitudinal data. Integrating sexual health assessment into routine care for people with NMDs should be prioritized.
- Open Access
- 22 April 2025
- Published by SAGE Publications in Journal of Neuromuscular Diseases
- Vol. 12 (4) , 487-496
A model to predict the 6-Minute Walk Distance in Pompe disease
Background: Pompe disease is a rare neuromuscular disorder caused by acid alpha-glucosidase deficiency, leading to glycogen accumulation and progressive striated muscle weakness. The 6-minute walk test (6MWT) is commonly used to assess functional capacity in neuromuscular diseases but can be challenging for severely affected ambulant patients. Objective: This study aimed to develop and validate predictive models for 6MWT performance using simpler, less demanding tests. Methods: This retrospective monocentric study included 74 patients with Pompe disease (712 visits) and a mean follow-up of 6.6 ± 3.8 years. Functional assessments included the 6MWT, 10-meter walk test (10mWT) which was specifically used to determine gait speed, timed tests, strength and respiratory measures, and the Motor Function Measure (MFM-32). Linear regression models were developed to predict 6MWT speed, with validation using an 80%-20% training-testing split. Results: The cohort had an equal male-to-female ratio, with a mean age of 54.4 ± 13.5 years. The 10mWT speed showed a strong correlation with 6MWT speed (R = 0.91, p < 0.0001), confirming its potential as a surrogate measure. The most practical predictive model included 10mWT speed, age, sex, height, and weight, achieving an adjusted R 2 of 0.86. This model balances simplicity and accuracy, relying on easily measurable parameters suitable for routine clinical use. More complex models, including variables such as the MFM-32 or supine-to-sit time, offered only marginal improvements in accuracy. Conclusion: The 10mWT offers a robust and less exhausting alternative to the 6MWT for assessing walking capacity in Pompe disease, particularly for ambulant patients with severe mobility limitations. Its strong correlation with the 6MWT and ease of implementation support its integration into clinical practice and trials.
- 22 April 2025
- Published by SAGE Publications in Journal of Neuromuscular Diseases
- Vol. 12 (4) , 487-496
Open AccessA model to predict the 6-Minute Walk Distance in Pompe disease
Background: Pompe disease is a rare neuromuscular disorder caused by acid alpha-glucosidase deficiency, leading to glycogen accumulation and progressive striated muscle weakness. The 6-minute walk test (6MWT) is commonly used to assess functional capacity in neuromuscular diseases but can be challenging for severely affected ambulant patients. Objective: This study aimed to develop and validate predictive models for 6MWT performance using simpler, less demanding tests. Methods: This retrospective monocentric study included 74 patients with Pompe disease (712 visits) and a mean follow-up of 6.6 ± 3.8 years. Functional assessments included the 6MWT, 10-meter walk test (10mWT) which was specifically used to determine gait speed, timed tests, strength and respiratory measures, and the Motor Function Measure (MFM-32). Linear regression models were developed to predict 6MWT speed, with validation using an 80%-20% training-testing split. Results: The cohort had an equal male-to-female ratio, with a mean age of 54.4 ± 13.5 years. The 10mWT speed showed a strong correlation with 6MWT speed (R = 0.91, p < 0.0001), confirming its potential as a surrogate measure. The most practical predictive model included 10mWT speed, age, sex, height, and weight, achieving an adjusted R 2 of 0.86. This model balances simplicity and accuracy, relying on easily measurable parameters suitable for routine clinical use. More complex models, including variables such as the MFM-32 or supine-to-sit time, offered only marginal improvements in accuracy. Conclusion: The 10mWT offers a robust and less exhausting alternative to the 6MWT for assessing walking capacity in Pompe disease, particularly for ambulant patients with severe mobility limitations. Its strong correlation with the 6MWT and ease of implementation support its integration into clinical practice and trials.
- Open Access
- 22 May 2024
- Published by SAGE Publications in Journal of Neuromuscular Diseases
- Vol. 11 (4) , 777-790
Relationship Between Hand Strength and Function in Duchenne Muscular Dystrophy and Spinal Muscular Atrophy: Implications for Clinical Trials
Background: Measurement of muscle strength and motor function is recommended in clinical trials of neuromuscular diseases, but the loss of hand strength at which motor function is impacted is not documented. Objectives: To establish the relationship between hand strength and function, and to determine the strength threshold that differentiates normal and abnormal hand function in individuals with Duchenne Muscular Dystrophy (DMD) or Spinal Muscular Atrophy (SMA). Methods: Maximal handgrip and key pinch strength were measured with the MyoGrip and MyoPinch dynamometers, respectively. Hand function was assessed using the MoviPlate, the Motor Function Measure items for distal upper limb (MFM-D3-UL) and the Cochin Hand Function Scale (CHFS). Results: Data from 168 participants (91 DMD and 77 SMA, age 6–31 years) were analyzed. Relationships between strength and function were significant ( P < 0.001). Hand function was generally preserved when strength was above the strength threshold determined by Receiver-Operating Characteristic (ROC) analysis: For MFM-D3-UL, the calculated handgrip strength thresholds were 41 and 13% of the predicted strength for a healthy subject (% pred) and the key pinch strength thresholds were 42 and 26% pred for DMD and SMA, respectively. For the MoviPlate, handgrip strength thresholds were 11 and 8% pred and key pinch strength thresholds were 21 and 11% pred for DMD and SMA, respectively. For participants with sub-threshold strength, hand function scores decreased with decreasing strength. At equal % pred strength, individuals with SMA had better functional scores than those with DMD. Conclusions: Hand function is strength-dependent for most motor tasks. It declines only when strength falls below a disease-specific threshold. Therefore, therapies capable of maintaining strength above this threshold should preserve hand function.
- 22 May 2024
- Published by SAGE Publications in Journal of Neuromuscular Diseases
- Vol. 11 (4) , 777-790
Open AccessRelationship Between Hand Strength and Function in Duchenne Muscular Dystrophy and Spinal Muscular Atrophy: Implications for Clinical Trials
Background: Measurement of muscle strength and motor function is recommended in clinical trials of neuromuscular diseases, but the loss of hand strength at which motor function is impacted is not documented. Objectives: To establish the relationship between hand strength and function, and to determine the strength threshold that differentiates normal and abnormal hand function in individuals with Duchenne Muscular Dystrophy (DMD) or Spinal Muscular Atrophy (SMA). Methods: Maximal handgrip and key pinch strength were measured with the MyoGrip and MyoPinch dynamometers, respectively. Hand function was assessed using the MoviPlate, the Motor Function Measure items for distal upper limb (MFM-D3-UL) and the Cochin Hand Function Scale (CHFS). Results: Data from 168 participants (91 DMD and 77 SMA, age 6–31 years) were analyzed. Relationships between strength and function were significant ( P < 0.001). Hand function was generally preserved when strength was above the strength threshold determined by Receiver-Operating Characteristic (ROC) analysis: For MFM-D3-UL, the calculated handgrip strength thresholds were 41 and 13% of the predicted strength for a healthy subject (% pred) and the key pinch strength thresholds were 42 and 26% pred for DMD and SMA, respectively. For the MoviPlate, handgrip strength thresholds were 11 and 8% pred and key pinch strength thresholds were 21 and 11% pred for DMD and SMA, respectively. For participants with sub-threshold strength, hand function scores decreased with decreasing strength. At equal % pred strength, individuals with SMA had better functional scores than those with DMD. Conclusions: Hand function is strength-dependent for most motor tasks. It declines only when strength falls below a disease-specific threshold. Therefore, therapies capable of maintaining strength above this threshold should preserve hand function.
- Open Access
- 29 January 2019
- Published by Wolters Kluwer Health in Neurology
- Vol. 92 (5) , e461-e474
Assessment of disease progression in dysferlinopathy
Objective To assess the ability of functional measures to detect disease progression in dysferlinopathy over 6 months and 1 year. Methods One hundred ninety-three patients with dysferlinopathy were recruited to the Jain Foundation9s International Clinical Outcome Study for Dysferlinopathy. Baseline, 6-month, and 1-year assessments included adapted North Star Ambulatory Assessment (a-NSAA), Motor Function Measure (MFM-20), timed function tests, 6-minute walk test (6MWT), Brooke scale, Jebsen test, manual muscle testing, and hand-held dynamometry. Patients also completed the ACTIVLIM questionnaire. Change in each measure over 6 months and 1 year was calculated and compared between disease severity (ambulant [mild, moderate, or severe based on a-NSAA score] or nonambulant [unable to complete a 10-meter walk]) and clinical diagnosis. Results The functional a-NSAA test was the most sensitive to deterioration for ambulant patients overall. The a-NSAA score was the most sensitive test in the mild and moderate groups, while the 6MWT was most sensitive in the severe group. The 10-meter walk test was the only test showing significant change across all ambulant severity groups. In nonambulant patients, the MFM domain 3, wrist flexion strength, and pinch grip were most sensitive. Progression rates did not differ by clinical diagnosis. Power calculations determined that 46 moderately affected patients are required to determine clinical effectiveness for a hypothetical 1-year clinical trial based on the a-NSAA as a clinical endpoint. Conclusion Certain functional outcome measures can detect changes over 6 months and 1 year in dysferlinopathy and potentially be useful in monitoring progression in clinical trials. ClinicalTrials.gov identifier: NCT01676077.
- 29 January 2019
- Published by Wolters Kluwer Health in Neurology
- Vol. 92 (5) , e461-e474
Open AccessAssessment of disease progression in dysferlinopathy
Objective To assess the ability of functional measures to detect disease progression in dysferlinopathy over 6 months and 1 year. Methods One hundred ninety-three patients with dysferlinopathy were recruited to the Jain Foundation9s International Clinical Outcome Study for Dysferlinopathy. Baseline, 6-month, and 1-year assessments included adapted North Star Ambulatory Assessment (a-NSAA), Motor Function Measure (MFM-20), timed function tests, 6-minute walk test (6MWT), Brooke scale, Jebsen test, manual muscle testing, and hand-held dynamometry. Patients also completed the ACTIVLIM questionnaire. Change in each measure over 6 months and 1 year was calculated and compared between disease severity (ambulant [mild, moderate, or severe based on a-NSAA score] or nonambulant [unable to complete a 10-meter walk]) and clinical diagnosis. Results The functional a-NSAA test was the most sensitive to deterioration for ambulant patients overall. The a-NSAA score was the most sensitive test in the mild and moderate groups, while the 6MWT was most sensitive in the severe group. The 10-meter walk test was the only test showing significant change across all ambulant severity groups. In nonambulant patients, the MFM domain 3, wrist flexion strength, and pinch grip were most sensitive. Progression rates did not differ by clinical diagnosis. Power calculations determined that 46 moderately affected patients are required to determine clinical effectiveness for a hypothetical 1-year clinical trial based on the a-NSAA as a clinical endpoint. Conclusion Certain functional outcome measures can detect changes over 6 months and 1 year in dysferlinopathy and potentially be useful in monitoring progression in clinical trials. ClinicalTrials.gov identifier: NCT01676077.
- 1 November 2017
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 122 (3) , 108-116
Long term longitudinal study of muscle function in patients with glycogen storage disease type IIIa
- 1 November 2017
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 122 (3) , 108-116
Long term longitudinal study of muscle function in patients with glycogen storage disease type IIIa
- 1 October 2017
- Published by Elsevier in Neuromuscular Disorders
- Vol. 27, S232-S233
Outcome measures for Duchenne muscular dystrophy from ambulant to non-ambulant patients: implications for clinical trials
- 1 October 2017
- Published by Elsevier in Neuromuscular Disorders
- Vol. 27, S232-S233
Outcome measures for Duchenne muscular dystrophy from ambulant to non-ambulant patients: implications for clinical trials
- 1 September 2017
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 122 (1-2) , 80-85
Effect of enzyme replacement therapy with alglucosidase alfa (Myozyme®) in 12 patients with advanced late-onset Pompe disease
- 1 September 2017
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 122 (1-2) , 80-85
Effect of enzyme replacement therapy with alglucosidase alfa (Myozyme®) in 12 patients with advanced late-onset Pompe disease
- 1 March 2017
- Published by Elsevier in Neuromuscular Disorders
- Vol. 27, S12
Outcome measures for Duchenne muscular dystrophy from ambulant to non-ambulant: implications for clinical trials
- 1 March 2017
- Published by Elsevier in Neuromuscular Disorders
- Vol. 27, S12
Outcome measures for Duchenne muscular dystrophy from ambulant to non-ambulant: implications for clinical trials
- Open Access
- 26 September 2016
- Published by Wiley in Developmental Medicine & Child Neurology
- Vol. 59 (2) , 224-231
Development of a patient‐reported outcome measure for upper limb function in Duchenne muscular dystrophy: DMD Upper Limb PROM
Aim: To develop a patient‐reported outcome measure (PROM) assessing upper limb function related to activities of daily living (ADL) that cannot be observed in a clinical setting, specifically for patients with Duchenne muscular dystrophy (DMD) across a wide age range, applicable in the different stages of the disease.Method: The developmental process was based on US Food and Drug Administration guidelines. This included item generation from a systematic review of existing tools and expert opinion on task difficulty and relevance, involving individuals with DMD. Cultural aspects affecting ADL were taken into consideration to make this tool applicable to the broad DMD community. Items were selected in relation to a conceptual framework reflecting disease progression covering the full range of upper limb function across different ADL domains.Results: After pilot testing and iterative Rasch analyses, redundant or clinically irrelevant items were removed. The final questionnaire consists of 32 items covering four domains of ADL (food, self‐care, household and environment, leisure and communication). Test–retest reliability was excellent.Interpretation: A DMD‐specific upper limb PROM was developed on the basis of clinical relevance and psychometric robustness. Its main purpose is to document the patient self‐reported natural history of DMD and assess the efficacy of interventions.
- 26 September 2016
- Published by Wiley in Developmental Medicine & Child Neurology
- Vol. 59 (2) , 224-231
Open AccessDevelopment of a patient‐reported outcome measure for upper limb function in Duchenne muscular dystrophy: DMD Upper Limb PROM
Aim: To develop a patient‐reported outcome measure (PROM) assessing upper limb function related to activities of daily living (ADL) that cannot be observed in a clinical setting, specifically for patients with Duchenne muscular dystrophy (DMD) across a wide age range, applicable in the different stages of the disease.Method: The developmental process was based on US Food and Drug Administration guidelines. This included item generation from a systematic review of existing tools and expert opinion on task difficulty and relevance, involving individuals with DMD. Cultural aspects affecting ADL were taken into consideration to make this tool applicable to the broad DMD community. Items were selected in relation to a conceptual framework reflecting disease progression covering the full range of upper limb function across different ADL domains.Results: After pilot testing and iterative Rasch analyses, redundant or clinically irrelevant items were removed. The final questionnaire consists of 32 items covering four domains of ADL (food, self‐care, household and environment, leisure and communication). Test–retest reliability was excellent.Interpretation: A DMD‐specific upper limb PROM was developed on the basis of clinical relevance and psychometric robustness. Its main purpose is to document the patient self‐reported natural history of DMD and assess the efficacy of interventions.